Ryan Cross interviewed our CEO, Dan Mandell, PhD, about how the Company’s GRO platform expands the limited amino acid alphabet that nature uses to make proteins, and how our Series...
Read More
Biotech TV host Brad Loncar visited GRObio’s office in Cambridge and had a discussion with GRObio CEO Dan Mandell, PhD about the Company’s recent Series B financing. In the interview,...
Read More
James Waldron reported on how GRObio’s $60.3 million Series B financing allows the Company to acquire clinical efficacy for its lead program in chronic refractory gout, and how our approach...
Read More
Hannah Green interviewed our CEO, Dan Mandell, PhD, about how GRObio’s ProGly-NSAAs prevent immune reactions that render many therapies ineffective, and how resolving this critical limitation is key to advancing...
Read More
Frank Vinluan interviewed our CEO, Dan Mandell, PhD, on GRO Biosciences’ platform for engineering therapeutic proteins without the immune reactions that often impair safety and efficacy, and how the Company’s...
Read More
Proceeds to advance clinical development of lead program for gout, broaden the Company’s pipeline, and expand its genomically recoded organism platform BOSTON, July 19, 2024 – GRO Biosciences Inc. (“GRObio”),…
